Potential Patchwork Of Local Drug Take-Back Programs Poses Problem For OTC Firms
This article was originally published in The Tan Sheet
Executive Summary
CHPA backs litigation challenging drug take-back requirements to help stave off a patchwork of similar programs. Consumer education requires “a long-term commitment and won't be cheap,” but the OTC industry “can push back against more onerous mandates, says CHPA chief Scott Melville.
You may also be interested in...
Trade Group News: CHPA Social Media Award, AHPA Prop 65 Guidance For CBD, CRN Workshop Speakers, More
AHPA supports 2020 Smithsonian Folklife Festival ginseng program; NPA offers to help Amazon following its notification of potentially counterfeit Align probiotics sold; CRN Day of Science tackles "Healthy Aging"; UNPA partners with hemp industry group; Expo East Herb Walk goes to Green Farmacy; CHPA Educational Foundation KnowYourOTCs campaign named "Social Media Campaign of Year" by PR Daily; and AHPA publishes California Prop 65 compliance guidance for CBD marketers.
State Officials Urging Rx Pseudoephedrine Face Strong Lobby
Officials from Mississippi, Missouri, Oregon and South Carolina and the National Narcotics Officers Associations Coalition testifying before a House subcommittee call for moving all PSE products to prescription status.
MoCRA’s Adulteration Ambiguity And FDA’s New Cosmetic Recall Authority: Attorney Weighs In
The US FDA should use guidance or rulemaking to clarify MoCRA provisions related to adulteration, Amin Wasserman Gurnani attorney Angela Diesch suggested at the Independent Beauty Association’s Cosmetics Convergence Spring Symposium. Attendees also sought her take on whether the agency’s new recall authority is likely to spell an increase in cosmetic product recalls.